Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement.

Mol Ther Oncol · 2025 · PMC12166800 · PMID 40520577

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Preliminary anti-tumor response Circulating tumor cells showed a trend to be reduced in cohort 3.1 for all markers assessed ( Figure 5 F).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.